{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:04:34Z","timestamp":1782489874614,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.imlet.2008.11.007","type":"journal-article","created":{"date-parts":[[2008,12,26]],"date-time":"2008-12-26T04:17:26Z","timestamp":1230265046000},"page":"108-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction"],"prefix":"10.1016","volume":"122","author":[{"given":"Kingston H.G.","family":"Mills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2008.11.007_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nri1485","article-title":"T cells: friend or foe in immunity to infection?","volume":"4","author":"Mills","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2008.11.007_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.onc.1210910","article-title":"TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours","volume":"27","author":"Conroy","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.imlet.2008.11.007_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","article-title":"Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cell","volume":"177","author":"Jarnicki","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib6","doi-asserted-by":"crossref","first-page":"13082","DOI":"10.1128\/JVI.78.23.13082-13089.2004","article-title":"CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1","volume":"78","author":"Toka","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.imlet.2008.11.007_bib7","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.4049\/jimmunol.175.11.7264","article-title":"Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance","volume":"175","author":"Moore","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.4049\/jimmunol.175.4.2517","article-title":"IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection","volume":"175","author":"Stober","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib9","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","article-title":"Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells","volume":"115","author":"Dannull","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2008.11.007_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1084\/jem.20020732","article-title":"Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody","volume":"196","author":"Vicari","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.imlet.2008.11.007_bib11","doi-asserted-by":"crossref","first-page":"7980","DOI":"10.4049\/jimmunol.177.11.7980","article-title":"TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells","volume":"177","author":"Higgins","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib12","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.4049\/jimmunol.171.10.4984","article-title":"Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos","volume":"171","author":"Agrawal","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib13","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.4049\/jimmunol.180.6.3797","article-title":"Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics","volume":"180","author":"Jarnicki","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.imlet.2008.11.007_bib14","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.vaccine.2008.04.005","article-title":"Therapeutic vaccination with dendritic cells pulsed with tumor-derived HSP70 and a COX-2 inhibitor induces protective immunity against B16 melanoma","volume":"26","author":"Toomey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2008.11.007_bib15","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1128\/IAI.00836-07","article-title":"Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses","volume":"76","author":"Fennelly","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.imlet.2008.11.007_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1084\/jem.20011288","article-title":"Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis","volume":"195","author":"McGuirk","year":"2002","journal-title":"J Exp Med"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247808002563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247808002563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:02:04Z","timestamp":1762250524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247808002563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0165247808002563"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2008.11.007","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2008.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}